SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline, particularly the FDA-cleared expansion of its REGAIN glioblastoma trial and upcoming clinical updates, alongside completed enrollment in its pancreatic-cancer IMPACT study. Traders are broadly bullish on the catalyst pipeline, though some are waiting for larger-cohort data to confirm the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook after earnings, amid softer PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are divided between calling the decline an overreaction and buying the dip, and seeing it as evidence of deeper execution and turnaround problems.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution and ex-dividend schedule as Nasdaq weakness weighs on the ETF. Traders are focused on the income and buying the dip, while others note that its covered-call strategy can cushionbut not preventlosses and may limit upside in a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish? 

Equity

Nasdaq cited ADTX’s long stretch below the $1 minimum bid rule and a $35.17 million stockholders’ equity deficit.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session.
Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their outstanding shares isread more...

ADTX Stock Surges 40% Overnight: New 10% Holder Emerges After Aditxt’s Ignite Proteomics SPAC Deal 

The filing said the stake was acquired for investment purposes, with no current plan “to change or influence control” of Aditxt.

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regular session. The market value of their outstanding shares is at $4.0 million.
Aditxt (NASDAQ:ADTX) shares moved upwardsread more...

AI, Biotech, And Healthcare Catalysts Drive Momentum

Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-market session. The company's market cap stands at $4.0 million.
Aditxt (NASDAQ:ADTX) shares rose 84.99% to $0.02.read more...

Nasdaq, S&P 500 Futures Surge As Wall Street Cheers US-Iran Deal, Brushes Off Hawkish Fed For Now: INTC, AAPL, MU, SPCX, RUM In Focus

Stocktwits data showed retail sentiment has improved to ‘bullish’ on SPY and QQQ from ‘bearish’ earlier in the week. 


Aditxt (ADTX) Stock Is Falling After Hours: What Is Going On?

Why Aditxt stock crashed after hours despite a new SEC filing showing Bank of America-linked share transactions.read more...

Aditxt (ADTX) Stock Surges Nearly 17% After Hours: Here's Why

Aditxt shares surged 16.92% after hours, extending intraday gains amid mixed SEC filing activity and corporate updates.read more...

ADTX Stock Rockets 90% Premarket: What's Fueling Rebound After A Record 22-Day Selloff?

Aditxt’s Ignite unit has signed a merger agreement with SPAC Copley Acquisition Corp. and is expected to become a standalone NYSE-listed company.

This account has been verified as an official ADTX representative.

Verified Account

Aditxt, Inc.

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.

Aditxt Inc

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>Aditxt shares are losing their Nasdaq listing after a panel rejected the company’s appeal over bid-price and stockholders’ equity failures.</li><li>Trading in ADTX common stock is set to be suspended at Thursday’s open, though the company can request a Nasdaq review within 15 days.</li><li>The panel was not persuaded by Aditxt’s proposed reverse split, noting that the company had already completed seven reverse splits.</li></ul>Shares of Aditxt, Inc. (ADTX) are losing their Nasdaq listing after a hearings panel rejected the company’s attempt to stay on the exchange, citing repeated failures to meet minimum bid price and stockholders’ equity requirements.<a href="https://stocktwits.com/symbol/ADTX">ADTX stock</a> crashed 77% on Wednesday and plunged another 19% in extended trading. Shares have shed nearly all of their value over the past year.<h2 class="st-heading-2">Nasdaq Pulls The Plug On ADTX</h2>Trading in ADTX common stock is set to be suspended at the open on Thursday, marking a major setback for the biotech company even as some retail traders bet on a potential comeback in OTC trading. Aditxt first received a Nasdaq delisting notice in May after its listed securities closed below the exchange’s $1 minimum bid price requirement for 30 straight business days, from March 24 through May 5.The company was not eligible for the usual 180-day compliance period as it had already carried out reverse stock splits over the past one and two years, including splits with a cumulative ratio of 250-to-1 or more. A second blow came later in May, when Nasdaq flagged Aditxt’s stockholders’ equity deficit of $35.17 million, far below the $2.5 million required for continued listing. The company also did not meet Nasdaq’s alternative standards based on market value or net income.Aditxt tried to keep its listing alive by laying out a recovery plan at a June 11 hearing, including another proposed reverse stock split at a ratio between 1-for-5 and 1-for-250. The company said it was targeting a post-split price of about $5. Nasdaq was not persuaded.The panel noted that Aditxt had already completed seven reverse stock splits, including a 1-for-113 split in November 2025, a 1-for-8 split in March and a 1-for-27 split last month. Even after these actions, the company failed to regain bid-price compliance. Nasdaq also noted that ADTX had closed below the $1 minimum bid price for about half of all trading days over the past two years. Aditxt may still request a review by Nasdaq’s Listing and Hearing Review Council within 15 days, though the company would have to pay a $15,000 review fee.&nbsp;<h2 class="st-heading-2">Ignite Deal Couldn’t Save ADTX Listing&nbsp;</h2>Aditxt’s biggest defense was Ignite Proteomics, its revenue-generating unit. Earlier this month, Aditxt signed a definitive agreement for Ignite to combine with Copley Acquisition Corp. in a deal valuing Ignite at about $150 million. The company said that the deal could increase stockholders’ equity by about $125 million and help it regain compliance by Sept. 15. It also said that Ignite could become an independent public company expected to trade on the NYSE, while Aditxt would continue as a separate listed company.But Nasdaq questioned the sharp valuation jump, the panel expressed skepticism over why Ignite, which Aditxt acquired in March for $35 million, had risen to a $150 million valuation within months. The panel also noted that, despite the clinical study cited by Aditxt and the Ignite deal, investors had not responded favorably to the company’s stock price.&nbsp;<h2 class="st-heading-2">ADTX Bulls Bet On OTC Comeback&nbsp;</h2>Despite the delisting decision, some retail traders are still leaning bullish, focusing on the possibility that ADTX could trade actively on the OTC market and that shareholders’ positions would carry over.On Stocktwits, retail sentiment for ADTX was ‘extremely bullish’ amid a 45,280% surge in message volumes over the past month. The ticker’s watcher base has also jumped 25% in the last three months.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/adtx_ss_png_45999676b0.webp" alt="adtx ss.png" width="972" height="131"><figcaption>ADTX sentiment and message volume as of June 25| Source: Stocktwits</figcaption></figure>One user called the shift to “PINK SHEETS” bullish,&nbsp;<a href="https://stocktwits.com/Ragnarok_74/message/657421517">saying</a>: “Yes! Very bullish now!” Another&nbsp;<a href="https://stocktwits.com/Gooo349/message/657420996">pointed</a> to Aditxt’s Nasdaq defense, saying that the company had claimed it could meet the $1 bid price and $2.5 million equity requirements by Sept.15.A third trader&nbsp;<a href="https://stocktwits.com/Drillerab1968/message/657411382">said</a> that OTC trading does not automatically mean the end of the story, writing: “The facts are just because it’s headed to the OTC isn’t the end of the world because your shares carry over.” The user cited the example of another company that traded OTC briefly and later returned to Nasdaq, saying: “The moral of the story there’s light at the end of the tunnel.”Meanwhile, a separate user&nbsp;<a href="https://stocktwits.com/Journey123098/message/657409235">said</a>: “I BOUGHT 50,000 SHARES RIGHT BEFORE CLOSING. THIS CAN GO UP HUGE IN OTC TOMORROW!”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-worst-month-2026-hk-primary-listing-upgrade/cZ1GIzHR7Q1">NIO Stock Tracks Worst Month In 2026: EV Maker Pursues Hong Kong Primary Listing Upgrade To Expand Investor Base&nbsp;</a>

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.0004
Prev Close	$0.0004
Open	$0.0004
Dividend Yield	0.00%
50-Day Moving Average	$0.0041
Beta	1.48
Avg. Volume	13.87M
PE Ratio	0.00

52-Week High	$1,540.56
52-Week Low	$0.0001
Market Capitalization	$399,191.00
EPS (Annual)	-$31,153.51
Price to Book	0.00
Revenue Per Employee	$122.89

Feed

News

Sentiment

Fundamentals

Info

ADTX Fundamentals